 we report on our fourth quarter and full year 2019 financial results and provide an update on our immuno-inflammatory pipeline. 
 we also provide an outlook for the fourth quarter of 2020 and look forward to delivering on the following catalyst in 2020. for ATI-450, we plan to initiate a phase 2 trial of rheumatoid arthritis in the first half of 2020 for subsequent data readout in the second half of 2020. for ATI-1777 or soft-JAK we plan to submit the IND in mid-2020 and initiate a phase 1/2 trial in the second half of 2020. and finally for ATI-2138, which is our investigational ITK/TXK/JAK3 inhibitor, we plan to submit the IND in late 2020 possibly early 2021.    # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 